500 related articles for article (PubMed ID: 25298038)
1. Biosimilars: the science of extrapolation.
Weise M; Kurki P; Wolff-Holz E; Bielsky MC; Schneider CK
Blood; 2014 Nov; 124(22):3191-6. PubMed ID: 25298038
[TBL] [Abstract][Full Text] [Related]
2. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
Agarwal AB; McBride A
Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.
Dingermann T; Scotte F
Expert Opin Biol Ther; 2016 Jul; 16(7):967-74. PubMed ID: 27227424
[TBL] [Abstract][Full Text] [Related]
4. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
6. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
8. Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
Krendyukov A; Schiestl M; Höbel N; Aapro M
Support Care Cancer; 2018 Jan; 26(1):33-40. PubMed ID: 28929372
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: what clinicians should know.
Weise M; Bielsky MC; De Smet K; Ehmann F; Ekman N; Giezen TJ; Gravanis I; Heim HK; Heinonen E; Ho K; Moreau A; Narayanan G; Kruse NA; Reichmann G; Thorpe R; van Aerts L; Vleminckx C; Wadhwa M; Schneider CK
Blood; 2012 Dec; 120(26):5111-7. PubMed ID: 23093622
[TBL] [Abstract][Full Text] [Related]
11. Will biosimilars gain momentum?
Hirsch BR; Lyman GH
J Natl Compr Canc Netw; 2013 Oct; 11(10):1291-7. PubMed ID: 24142828
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of biosimilar epoetins in nephrology in the United States.
Fishbane S; Shah HH
Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
[TBL] [Abstract][Full Text] [Related]
13. [Biosimilar drugs in oncology].
Levêque D
Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
[TBL] [Abstract][Full Text] [Related]
14. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
15. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
[TBL] [Abstract][Full Text] [Related]
17. Update on biosimilars of granulocyte colony-stimulating factor - when no news is good news.
Schulz M; Bonig H
Curr Opin Hematol; 2016 Jan; 23(1):61-6. PubMed ID: 26554886
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
19. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
